September 5, 2024
Speakers: Bernard V. Fallon, Louisa Conklin, Ravi Kiron, PhD, MBA, Carolyn Ng, PhD, Ruchita Sinha, MBA
So far, 2024 biotech markets and funding are trending better than last year, but volatility is on the upswing. Join this webinar to hear experienced perspectives on what investment signals to be watching to position yourself for a strong springboard into closing out the year…
![Investors](/sites/default/files/styles/bio_media_side_card_auto/public/2019-10/48944836107_a500b61ab2_w.jpg?itok=KWR9VdxU)
November 14, 2024
Speakers: Mackensie Vernetti
BIO One-on-One Partnering™ is back at the San Francisco Marriott Marquis for JPM Week 2025 and with 70% more meeting space! Attend this webinar to hear about how BIO’s partnering system can help you source new partnerships and manage your meetings for JPM Week. Learn about BIO’s…
![partnering](/sites/default/files/styles/bio_media_side_card_auto/public/2023-06/partnering_story.png?itok=cJcSdjHa)
![BIO 2024 BIF Conference logo](/sites/default/files/2024-08/bio_bif2024_logo_small.png)
So far, 2024 biotech markets and funding are trending better than last year, but volatility is on the upswing. Join this webinar to hear experienced perspectives on what investment signals to be watching to position yourself for a strong springboard into closing out the year before JPM Week restarts the cycle. This webinar will also preview the panel topics and speakers for the upcoming BIO Investor Forum as well as demonstrate how best to utilize the event’s BIO One-on-One Partnering System to connect with investors and more.
![2024 BIO Asia Taiwan Webinar_resized image v1.1](/sites/default/files/2024-06/image_2024_bio_asia_logo-v-date_resized_v1.1.jpg)
Join this webinar to learn about the many exciting opportunities available at the 2024 BIO Asia-Taiwan International Conference & Exhibition. This live web event will cover:
- Overview of the event schedule
- Preview of conference sessions and programming
- Live demo of the BIO One-on-One Partnering system, including new features such as Optional Meeting – Participants, to enhance your business partnering experience
- Q&A with the speakers
Date: June 21, 9:00 a.m. Taipei Standard Time / June 20, 9:00 p.m. EDT
![Touchlight](/sites/default/files/2023-02/thumbnails%207.png)
More than $4B of deals between biopharma companies and AI specialists were announced last year. Similar to the massive quality leap from GPT-2 to GPT-4 and the record-breaking consumer adoption rates of AI tools, that same exponential progress and uptake is coming to biotech AI. 2024 may bring the first one-trillion-parameter protein language model. Companies are already using AI to program, as opposed to discover, antibodies. This level of opportunity and change brings with it urgency—— companies need to rethink from the ground up how their R&D should work to compete in a new era defined by the intersection of biology, data, and AI.
In this webinar, learn how companies are updating their approach to R&D, with a focus on:
- AI-Ready Data: Improving generation of high-quality biomedical data to support AI model building and model tuning
- AI-Enabled Scientists: Integrating the right models directly into scientists’ workflows for everyday use
- Scalability: Making performance, speed, privacy, and cost tradeoffs for deployment of AI, and connecting the wet and dry labs
![Patient with doctor image](/sites/default/files/2024-01/image_pop-up_and_card_patient_with_doctor.jpg)
The FDA has established the Split Real-Time Application Review (STAR) pilot program. The purpose of this program is to shorten the time from the date of a complete submission to the action date, in allowing earlier patient access to therapies that address an unmet medical need.
In this webinar, FDA staff will give an overview of the program, including the eligibility criteria for the pilot, and will answer your questions about participating in the program.
![Image of a board meeting in a meadow](/sites/default/files/2023-07/webinar_esg_field1.png)
View this conversation highlighting how BIO member companies are leveraging biotechnology innovations to enable advances in climate adaptation, mitigation, and resilience. Hear how diverse feedstocks and manufacturing processes are targeting emission reduction breakthroughs in hard-to-reach sectors. Learn how regulation and policy can better incentivize innovation and be structured to support new and emerging technologies throughout research, development, demonstration, and deployment.
![photo of pills in capped bottles](/sites/default/files/2023-08/caps_over_pills_480x589.png)
It's been one year since the passage of the IRA. The Centers for Medicare & Medicaid Services has moved forward implementing the law's various provisions, including the new Medicare negotiation program and the redesign of the Medicare Part D benefit. Learn the latest developments from our panel of experts, including how the IRA is impacting biopharmaceutical companies today. Panelists delve into other important issues beyond the IRA, including new developments in Medicaid, 340B, and the emergence of Prescription Drug Affordability Boards in a number of states.
![Globe](/sites/default/files/2019-11/MSC_Globe.png)
Following reauthorization by Congress of the SBIR/STTR Programs in 2022, there are new rules companies should familiarize themselves with concerning required disclosures of foreign affiliations or relationships with foreign countries. In addition to mandating disclosures prior to receiving SBIR awards, companies must also regularly update NIH following any changes to a disclosure. View this webinar organized by the Biotechnology Innovation Organization (BIO) for a comprehensive discussion on how to effectively navigate these new rules as you apply for SBIR awards.
This webinar is co-hosted by the National Institutes of Health (NIH) Seed Office.
![scientist looking at molecule ideas](/sites/default/files/2023-08/tech-transfer_labcoat_-896x667.png)
With the majority of biological studies conducted in academic settings but nearly all innovative new drug clinical trials sponsored by industry, improving translational research success rates for commercialization is critical to bringing new treatments to patients. Surveys of academic tech transfer offices and the biopharma industry executives working on such alliances cite as obstacles two highly controllable factors: disagreement about alliance performance metrics and misalignment of deal terms priorities. This panel discusses best practices for removing such obstacles to accelerate more promising ideas into clinical development for patients.
BIO's updated 2023 report, "U.S. Biotechnology Translational Research: Partnership Models, Management Principles, and Best Practices," is available for download at the link below. The webinar also summarizes major findings from that BIO report as context for the panel discussion and audience Q&A.
![BTN-MTC_Researchers-DNA-364x210](/sites/default/files/2019-11/BTN-MTC_Researchers-DNA-364x210.png)
The Cell and Gene Therapy (CGT) Science Series is a quarterly seminar series focused on scientific topics related to cell and gene therapy products. The CGT Science Series is intended to foster scientific exchange between the Biotechnology Innovation Organization (BIO), the American Society of Cell & Gene Therapy (ASGCT), and Center for Biologics Evaluation and Research (CBER) review staff on a variety of topics that span the CGT product lifecycle. The seminars are planned as 60-minute virtual webinars featuring a speaker from one of the three organizations. The CGT Science Series will enable a deep dive into a specific technical and/or scientific area. Topics in the series may include but are not limited to, nonclinical, CMC, clinical, or post-market phases of development related to CGT product lifecycle.
Moderator:
– Anne-Virginie Eggimann, Tessera
Opening Remarks:
– Cartier Esham, Senior Advisor, Biotechnology Innovation Organization (BIO)
Speaker:
– Jing Liao, Director, Vector Development and Operations, Alexion Pharmaceuticals
![Placeholder Image](/act-root/bio/assets/images/webinar-popup-default.jpg)
This Biotechnology Innovation Organization (BIO) webinar explains that the days of the one-page marketing slicks are over, as companies and investors now expect brief “Pitch Decks” when engaging in conversations with them. This diverse panel of experts explain how to make an effective pitch to them, so that you can tailor your BIO partnering strategy to achieve a maximum ROI.
![Balloon in storm clouds photo](/sites/default/files/2023-04/stormy-clouds-and-balloon.png)
During this webinar, panelists discuss strategies for biotechnology companies to manage economic downturns and weakened investor interest in the biotech industry. Our expert panel of industry leaders share their insights and experiences on how to maintain momentum and emerge stronger during periods of economic uncertainty.
This webinar is designed to provide practical advice and actionable strategies that can be implemented immediately. The panel covers the following topics:
• Effective communication and investor relations strategies during economic downturns
• Actions biotechs can take to cut costs without sacrificing innovation and growth
• How to pitch to investors during weakened investor interest periods
![Loudspeaker and caution tape image](/sites/default/files/2023-04/illustration_of_cautious_communication_recrop.png)
U.S. Department of Justice (DOJ) statistics suggest that enforcement will be a top government priority in 2023, including for pharma/life sciences. Warning or untitled letters from the U.S. Food and Drug Administration (FDA) will serve as ammunition for DOJ cases. Statements about product safety will be heavily scrutinized.
Do you know what to watch out for? Has your company trained its employees and marketing agencies on how to appropriately implement the requirements for promotion? What activities require extra vigilance? The prior downturn in enforcement can be linked to the development of a response to COVID-19, which diverted government resources across the board. Now trends suggest the FDA, DOJ, and Office of Inspector General (OIG) will return to active healthcare enforcement in 2023 for violations of the Food Drug and Cosmetic Act (FDCA), False Claims Act and the Anti-Kickback Statute in part attributable to the goal of obtaining additional financial recoveries.
This webinar hosted by the Biotechnology Innovation Organization (BIO) has these learning objectives:
—Understand the current trends for government enforcement
—Dissect the compliance implications of increased enforcement on the industry
—Identify specific cases that are clear examples for company concern
—Isolate the key principles for avoiding violations
ON-DEMAND
COMMUNICATIONS COMPLIANCE COURSES
FOR PROFESSIONAL DEVELOPMENT
Special Discount
Buy 2 course registrations, Get 1 FREE
through May 15, 2023
in honor of this webinar!
The Center for Communication Compliance (CCC) helps biopharmaceutical companies achieve efficient, compliant innovation in a digital world through its proprietary on-demand business solutions in education, technology, and change management.
The CCC eLearning System has set an unmatched standard for confirming regulatory competency through engaging mastery tests and expert education content across more than a dozen course options.
SEE COURSES LIST
![partnering](/sites/default/files/2023-06/partnering_story.png)
BIO One-on-One Partnering™ is back at the San Francisco Marriott Marquis for JPM Week 2025 and with 70% more meeting space! Attend this webinar to hear about how BIO’s partnering system can help you source new partnerships and manage your meetings for JPM Week. Learn about BIO’s onsite meeting space in San Francisco, tips and tricks for using the system, and how to schedule your meetings with different location options. Also, get a look at how you can stay in-the-know about networking and other opportunities during JPM Week. For more information about BIO Partnering at JPM Week, please visit: https://www.bio.org/events/bio-partnering-jpm/registration
This live virtual event will cover:
- Preview of BIO’s onsite meeting space in San Francisco
- Partnering best practices & how to schedule your meetings
- Live demo of the partnering system & advanced features
- Intro to BIO and Novateur Ventures’ JPM Week Events Guide mobile app
- Q&A with the host
![BIO 2024 BIF Conference logo](/sites/default/files/2024-08/bio_bif2024_logo_small.png)
So far, 2024 biotech markets and funding are trending better than last year, but volatility is on the upswing. Join this webinar to hear experienced perspectives on what investment signals to be watching to position yourself for a strong springboard into closing out the year before JPM Week restarts the cycle. This webinar will also preview the panel topics and speakers for the upcoming BIO Investor Forum as well as demonstrate how best to utilize the event’s BIO One-on-One Partnering System to connect with investors and more.
![2024 BIO Asia Taiwan Webinar_resized image v1.1](/sites/default/files/2024-06/image_2024_bio_asia_logo-v-date_resized_v1.1.jpg)
Join this webinar to learn about the many exciting opportunities available at the 2024 BIO Asia-Taiwan International Conference & Exhibition. This live web event will cover:
- Overview of the event schedule
- Preview of conference sessions and programming
- Live demo of the BIO One-on-One Partnering system, including new features such as Optional Meeting – Participants, to enhance your business partnering experience
- Q&A with the speakers
Date: June 21, 9:00 a.m. Taipei Standard Time / June 20, 9:00 p.m. EDT
![photo of pills in capped bottles](/sites/default/files/2023-08/caps_over_pills_480x589.png)
Through 2027, the FDA is conducting a Chemistry, Manufacturing, and Controls (CMC) Development and Readiness Pilot (CDRP) Program to facilitate CMC development of selected products under investigational new drug applications with potential expedited clinical development timeframes. The pilot is a joint effort by both FDA's Center for Biologics Evaluation and Research (CBER) and the Center for Drug Evaluation and Research (CDER). Selected drug development programs receive extra opportunities to discuss product-specific CMC concerns with the FDA reviewers through CMC-focused Type B meetings to help product development keep pace with their clinical development.
In combination with PhRMA and the FDA, BIO hosted a webinar to inform BIO and PhRMA's memberships about the CDRP: What sorts of products are eligible, what is needed to apply, and why an IND sponsor of a promising product with an expedited clinical development timeframe would want to enlist in this pilot. This webinar will provide additional insights into the CDRP application process, and the planned public workshop designed to promote innovation and understanding in product development.
![Partnering in motion5](/sites/default/files/2024-02/image_partnering-in-action5.jpeg)
This webinar will help BIO 2024 attendees/exhibitors better prepare for their on-site experience at the event. We will provide important and practical on-site information, including programming and interactive event opportunities, as well as further instruction on how to more effectively use advanced features of the BIO One-on-One Partnering™ and Exhibitor platforms.
Gain valuable insights to make the most out of your participation at the upcoming BIO International Convention in San Diego this June!
To learn more about attending BIO 2024, visit http://convention.bio.org
![Touchlight](/sites/default/files/2023-02/thumbnails%207.png)
More than $4B of deals between biopharma companies and AI specialists were announced last year. Similar to the massive quality leap from GPT-2 to GPT-4 and the record-breaking consumer adoption rates of AI tools, that same exponential progress and uptake is coming to biotech AI. 2024 may bring the first one-trillion-parameter protein language model. Companies are already using AI to program, as opposed to discover, antibodies. This level of opportunity and change brings with it urgency—— companies need to rethink from the ground up how their R&D should work to compete in a new era defined by the intersection of biology, data, and AI.
In this webinar, learn how companies are updating their approach to R&D, with a focus on:
- AI-Ready Data: Improving generation of high-quality biomedical data to support AI model building and model tuning
- AI-Enabled Scientists: Integrating the right models directly into scientists’ workflows for everyday use
- Scalability: Making performance, speed, privacy, and cost tradeoffs for deployment of AI, and connecting the wet and dry labs
![Partnering in motion4](/sites/default/files/2024-02/image_partnering-in-action4.jpeg)
The BIO International Convention attracts 15,000+ biotechnology and pharma leaders for one week of intensive networking to discover new opportunities and promising partnerships. Position yourself for success at this year's event, June 3-6, in San Diego! BIO is where business and breakthroughs converge – and the BIO One-on-One Partnering™ system facilitates the connections that fuel our industry.
Attend this webinar to learn more about what’s happening at BIO 2024 and what the BIO One-on-One Partnering™ system can do for your business goals. Explore the program, networking opportunities, partnering system fundamentals, gain insight to best practices for partnering, and much more! For more information and to register for BIO 2024, please visit: convention.bio.org
![BIO 2024 Exhibit Hall](/sites/default/files/2024-01/image_bio_2024_exhibit_hall.jpg)
Join BIO staff as they walk exhibitors through the tools needed to plan for BIO International 2024!
The goal of this webinar is to provide our exhibitors with the resources to have an impactful presence in San Diego as well as provide additional details.
The following topics will be discussed:
- Exhibitor Dashboard
- Exhibitor Resources
- Exhibitor Partnering
- Important Dates and Deadlines
- Frequently Asked Questions (FAQs)
![Patient with doctor image](/sites/default/files/2024-01/image_pop-up_and_card_patient_with_doctor.jpg)
The FDA has established the Split Real-Time Application Review (STAR) pilot program. The purpose of this program is to shorten the time from the date of a complete submission to the action date, in allowing earlier patient access to therapies that address an unmet medical need.
In this webinar, FDA staff will give an overview of the program, including the eligibility criteria for the pilot, and will answer your questions about participating in the program.